Johnson & Johnson, AstraZeneca and GlaxoSmithKline side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Johnson & Johnson | AstraZeneca | GlaxoSmithKline |
|---|---|---|---|
| Phase 1 | Johnson & Johnson: 26 of its 56 programs at phase 1
and 21 more — sign in to see them all | AstraZeneca: 25 of its 119 programs at phase 1
and 20 more — sign in to see them all | GlaxoSmithKline: 19 of its 88 programs at phase 1
and 14 more — sign in to see them all |
| Phase 2 | Johnson & Johnson: 8 of its 56 programs at phase 2
and 3 more — sign in to see them all | AstraZeneca: 47 of its 119 programs at phase 2
and 42 more — sign in to see them all | GlaxoSmithKline: 36 of its 88 programs at phase 2
and 31 more — sign in to see them all |
| Phase 3 | Johnson & Johnson: 18 of its 56 programs at phase 3
and 13 more — sign in to see them all | AstraZeneca: 28 of its 119 programs at phase 3
and 23 more — sign in to see them all | GlaxoSmithKline: 23 of its 88 programs at phase 3
and 18 more — sign in to see them all |
| Approved, new studies | Johnson & Johnson: 4 of its 56 programs at approved, new studies
| AstraZeneca: 19 of its 119 programs at approved, new studies
and 14 more — sign in to see them all | GlaxoSmithKline: 10 of its 88 programs at approved, new studies
and 5 more — sign in to see them all |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson26 readouts · 8 phase 3 | Johnson & Johnson, Nov ’26: 1 program whose next study reaches primary completion
| Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3
and 4 more — sign in to see them all | Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion
| Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3
| Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion
| Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| · | Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion
| · | Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion
| · | Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion
|
| AstraZeneca61 readouts · 16 phase 3 | AstraZeneca, Nov ’26: 6 programs whose next study reaches primary completion
and 1 more — sign in to see them all | AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3
and 2 more — sign in to see them all | AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3
and 7 more — sign in to see them all | AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3
and 2 more — sign in to see them all | AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion
| AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3
| AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion
| AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion
| AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion
| AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3
|
| GlaxoSmithKline40 readouts · 8 phase 3 | GlaxoSmithKline, Nov ’26: 4 programs whose next study reaches primary completion, 2 in phase 3
| GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3
and 1 more — sign in to see them all | GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion
| GlaxoSmithKline, Feb ’27: 1 program whose next study reaches primary completion
| GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3
and 1 more — sign in to see them all | GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion
| GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion
| GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3
| GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion
| GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion
|
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Johnson & Johnson
New programs 1
- JNJ-99220732phase 1 · first study · Nov 12 · Neoplasms
Reached a new phase 2
- Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915phase 3 · Oct 26 · Prostatic Neoplasms
- deulumateperonephase 3 · Sep 2 · Generalized Anxiety Disorder
Study stopped 0
None
Primary completion later 3
- bleximenibphase 2 · Feb 2027 → Dec 2028 (+22 mo) · moved Nov 4 · NCT04811560
- teclistamabapproved, new study · Nov 2026 → Feb 2027 (+3 mo) · moved Nov 3 · NCT07030517
- Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Dec 2026 → Jun 2027 (+6 mo) · moved Oct 26 · NCT06150157
AstraZeneca
New programs 2
- CT204V-CD19 × CD20phase 2 · first study · Nov 6
- AZD0543phase 1 · first study · Aug 28 · Paramyxoviridae Infections
Reached a new phase 1
- BFF MDIphase 3 · Nov 6 · Asthma
Study stopped 0
None
Primary completion later 23
- AZD4954phase 1 · Dec 2026 → Mar 2027 (+3 mo) · moved Nov 13 · NCT07812077
- laroprovstatphase 3 · Jul 2025 → Feb 2027 (+20 mo) · moved Nov 13 · NCT06834932
- saruparibphase 1 · Oct 2026 → Dec 2026 (+3 mo) · moved Nov 12 · NCT06713369
- elecoglipronphase 1 · Oct 2026 → Jan 2027 (+4 mo) · moved Nov 10 · NCT07534592
- rilvegostomigphase 2 · Aug 2026 → Jun 2028 (+21 mo) · moved Nov 10 · NCT04995523
- rosuvastatinphase 1 · Oct 2026 → Jan 2027 (+4 mo) · moved Nov 10 · NCT07534592
+17 more
- ALXN2230phase 1 · Dec 2026 → Aug 2027 (+8 mo) · moved Nov 5 · NCT07352423
- monalizumabphase 3 · Sep 2026 → Jan 2027 (+3 mo) · moved Nov 4 · NCT05221840
- oleclumabphase 3 · Sep 2026 → Jan 2027 (+3 mo) · moved Nov 4 · NCT05221840
- Anti-CD22/Topoisomerase I Inhibitor Antibody-drug Conjugate AZD4512phase 2 · Mar 2028 → Jul 2028 (+4 mo) · moved Nov 2 · NCT07123454
- vemzatatug vedotinphase 2 · Aug 2027 → Jan 2028 (+5 mo) · moved Oct 30 · NCT06106945
- surovatamigphase 2 · Jun 2029 → May 2030 (+11 mo) · moved Oct 28 · NCT06564038
- trastuzumab deruxtecanphase 3 · Nov 2026 → May 2027 (+6 mo) · moved Oct 22 · NCT04784715
- Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Oct 2028 → Nov 2028 (+1 mo) · moved Oct 21 · NCT07735637
- surovatamigphase 2 · Apr 2028 → Oct 2028 (+6 mo) · moved Oct 20 · NCT07571746
- Anti-CD22/Topoisomerase I Inhibitor Antibody-drug Conjugate AZD4512phase 2 · Apr 2028 → Oct 2028 (+5 mo) · moved Oct 15 · NCT07109219
- datopotamab deruxtecanphase 3 · Sep 2026 → Jan 2027 (+3 mo) · moved Oct 15 · NCT06417814
- osimertinibphase 3 · Sep 2026 → Jan 2027 (+3 mo) · moved Oct 15 · NCT06417814
- acalabrutinibphase 3 · Jan 2027 → Apr 2027 (+3 mo) · moved Oct 5 · NCT03836261
- elecoglipronphase 3 · Jun 2027 → Apr 2028 (+10 mo) · moved Oct 1 · NCT07775404
- AZD9550phase 2 · Aug 2026 → Oct 2026 (+3 mo) · moved Sep 29 · NCT07017179
- lenbelintidephase 2 · Aug 2026 → Oct 2026 (+3 mo) · moved Sep 29 · NCT07017179
- Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863phase 2 · Jul 2027 → Mar 2029 (+20 mo) · moved Sep 25 · NCT06005493
GlaxoSmithKline
New programs 5
- GSK5864399phase 2 · first study · Nov 12 · Colorectal Neoplasms
- VH5356136phase 1 · first study · Sep 10 · HIV Infections
- VH4367310phase 1 · first study · Sep 8 · HIV Infections
- mRNA Seasonal Flu vaccinephase 3 · first study · Sep 1 · Influenza, Human
- ganfeborolephase 1 · first study · Aug 21 · Tuberculosis
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 10
- dostarlimabphase 3 · Dec 2029 → Mar 2030 (+3 mo) · moved Nov 16 · NCT07740720
- VH4524184phase 2 · Jun 2027 → Oct 2027 (+5 mo) · moved Nov 12 · NCT07202546
- VH4524184phase 1 · Jan 2028 → May 2029 (+16 mo) · moved Nov 5 · NCT06310551
- dostarlimabphase 2 · Jul 2026 → Dec 2026 (+5 mo) · moved Nov 2 · NCT06317311
- GSK5926371phase 2 · Sep 2029 → Jan 2030 (+4 mo) · moved Oct 30 · NCT07607925
- aletekitugphase 1 · Jul 2028 → Mar 2029 (+8 mo) · moved Oct 28 · NCT07747467
+4 more
- risvutatug rezetecanphase 2 · Jan 2028 → Jan 2029 (+12 mo) · moved Oct 19 · NCT06885034
- mocertatug rezetecanphase 3 · Dec 2029 → Jul 2030 (+7 mo) · moved Oct 15 · NCT07286266
- GSK4771261phase 1 · Sep 2026 → May 2027 (+8 mo) · moved Oct 5 · NCT07600450
- risvutatug rezetecanphase 1 · Jul 2026 → Feb 2028 (+19 mo) · moved Sep 25 · NCT07277270
Where they overlap
Conditions where at least two of them have programs: 54 in all, the first 12 here. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Johnson & Johnson: 4, AstraZeneca: 5, GlaxoSmithKline: 17).